Ethnicity, race, and clinically significant macular edema in the Veterans Affairs Diabetes Trial (VADT)

Diabetes Research and Clinical Practice

Volumn 86, Issue 2, 2009, Pages 104-110

  Emanuele, Nicholas ^a   Moritz, Thomas ^b   Klein, Ronald ^c   Davis, Matthew D ^d   Glander, Kathleen ^d   Khanna, Anuradha ^a   Thottapurathu, Lizy ^b   Bahn, Gideon ^b   Duckworth, William ^e   Abraira, Carlos ^f  

^a HINES VA HOSPITAL   (United States)

^b Hines VA Cooperative Studies Program Coordinating Center   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e CARL T HAYDEN VA MEDICAL CENTER   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Ethnicity; Macular edema; Risk factors

Indexed keywords

ALBUMIN; CREATININE; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE;

ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; AMPUTATION; ARTICLE; BIOCHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DEMOGRAPHY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; ETHNIC DIFFERENCE; HIGH RISK POPULATION; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; OPHTHALMOSCOPY; PREVALENCE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VETERAN;

AGE OF ONSET; AGED; AMPUTATION; ANALYSIS OF VARIANCE; CONTINENTAL POPULATION GROUPS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MACULAR EDEMA; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PATIENT SELECTION; PREVALENCE; STROKE; VETERANS;

EID: 70349769159     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.08.001     Document Type: Article

References (34)

1. Abraira C., Duckworth W., McCarren M., Emanuele N., Arca D., Reda D., and Henderson W. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2 (Veterans Affairs Diabetes Trial). J. Diabetes Complications 17 (2003) 314-322
2. Emanuele N., Sacks J., Klein R., Reda D., Anderson R., Duckworth, and Abraira C. Ethnicity, race and basal retinopathy correlates in the Veterans Diabetes Trial. Diabetes Care 28 (2005) 1954-1958
3. Wong T.-Y., Klein R., Islam A., Cotch M.F., Folsom A., Klein B., et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am. J. Ophthalmol. 141 (2006) 446-455
4. The Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch. Ophthalmol. 122 (2004) 552-563
5. Emanuele N., Klein R., Abraira C., Colwell J., Comstock J., Henderson W.G., et al. Evaluations of retinopathy in the VA Cooperative Study on glycemic control and complications in Type II diabetes (VA CSDM): a feasibility study. Diabetes Care 19 (1996) 1375-1381
6. Klein R., Moss S., Klein B., Davis M., and DeMets D. The Wisconsin Epidemiologic Study of diabetic retinopathy. XI. The incidence of macular edema. Ophthalmology 96 (1989) 1501-1510
7. Harris M., Klein R., Cowie C., Rowland M., and Byrd-Holt D. Is the risk of diabetic retinopathy greater in Non-Hispanic Blacks and Mexican Americans than in Non-Hispanic Whites with Type 2 Diabetes?: A US Population Study. Diabetes Care 21 (1998) 1230-1235
8. Harris E., Sherman S., and Georgopoulos A. Black-White differences in risk of developing retinopathy among individuals with Type 2 diabetes. Diabetes Care 22 (1999) 779-783
9. Lopes de Faria J., Jalkh A., Trempe C., and McMeel J. Diabetic macular edema: risk factors and concomitants. Acta Ophthalmol. Scand. 77 (1999) 170-175
10. Aroca P., Salvat M., Fernandez J., and Mendez I. Risk factors for diffuse and focal macular edema. J. Diabetes Complications 18 (2004) 211-215
11. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
12. Schrier R., Estacio R., Esler A., and Mehler P. Effects of aggressive blood pressure control in normotensive Type 2 diabetic patients on albuminuria, retinopathy, and strokes. Kidney Int. 61 (2002) 1066-1076
13. UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in Type 2 diabetes mellitus. Arch. Opthalmol. 122 (2004) 1631-1640
14. Juutilainen A., Seppo L., Tapani R., Pyorala K., and Laasko M. Retinopathy predicts cardiovascular mortality in Type 2 diabetic men and women. Diabetes Care 30 (2007) 292-299
15. Cheung N., Wang J., Klein R., Couper D., Sharrett A., and Wong T. Diabetic retinopathy and the risk of coronary heart disease. Diabetes Care 30 (2007) 1742-1746
16. Reaven P., Emanuele N., Moritz T., Klein R., Davis M., Glander K., Duckworth W., and Abraira C. Proliferative diabetic retinopathy in Type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 31 (2008) 952-957
17. Ciulla T., Amador A., and Zinman B. Diabetic retinopathy and diabetic macular edema. pathophysiology, screening, and novel therapies. Diabetes Care 26 (2003) 2653-2664
18. Williams R., Airey M., Baxter H., Forrester J., Kennedy-Martin T., and Girach A. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye 18 (2004) 963-983
19. Fujisawa T., Ikegami H., Yamato E., Kawaguch Y., Ueda H., Shintani M., et al. Association of plasma fibrinogen level and blood pressure with diabetic retinopathy, and renal complications associated with proliferative diabetic retinopathy, in Type 2 diabetes mellitus. Diab. Med. 16 (1999) 522-526
20. Wong J., Molyneaux L., Costantino M., Twigg S., and Yue D. Timing is everything: age of onset influences long-term retinopathy risk in Type 2 diabetes. Independent of traditional risk factors. Diabetes Care 31 (2008) 1985-1990
21. Knudsen S., Bek T., Poulsen P., Hove M., Rehling M., and Morgensen C. Macular edema reflects generalized vascular hyperpermeability in Type 2 diabetic patients with retinopathy. Diabetes Care 25 (2002) 2328-2334
22. Cusick M., Chew E., Chan C., Kruth H., Murphy R., and Ferris F. Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels. Ophthalmology 110 (2003) 2126-2133
23. Ferris F., Chew E., and Hoogwerf B. Serum lipids and diabetic retinopathy. Diabetes Care 19 (1996) 1291-1293
24. Chew E., Klein M., Ferris F., Remaley N., Murphy R., Chantry K., Hoogwerf B., and Miller D. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy: Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch. Opthalmol. 114 (1996) 1079-1084
25. Klein B., Moss S., Klein R., and Surawicz T. The Wisconsin Epidemiologic Study of diabetic retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 98 (1991) 1261-1265
26. Rema M., Srivastava B., Anitha B., Deepa R., and Mohan V. Association of serum lipids with diabetic retinopathy in Urban South Indians-the Chennai Urban Rural Epidemiology Study (CURES) Eye Study 2. Diabet. Med. 23 (2006) 1029-1036
27. El-Asrar A., Al-Rubeaan K., and Al-Amro S. Risk factors for diabetic retinopathy among Saudi diabetics. Int. Opthalmol. 22 (1998) 155-161
28. Gordon B., Chang S., and Kavanaugh M. The effect of lipid lowering on diabetic retinopathy. Am. J. Ophthalmol. 112 (1991) 385-391
29. Sen K., Misra A., Kumar A., and Pandey R. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res. Clin. Pract. 56 (2002) 1-11
30. Gupta A., Ggupta V., Thapar S., and Bhansali A. Lipid lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am. J. Ophthalmol. 137 (2004) 675-682
31. Zhang J., and McGwin G. Association of statin use with the risk of developing diabetic retinopathy. Arch. Opthalmol. 125 (2007) 1096-1099
32. FIELD Study Investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet 370 (2007) 1687-1697
33. Coluccielo M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch. Ophthalmol. 123 (2005) 1273-1275
34. Diabetes Prevention Program Research Group. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the diabetes prevention program. Diabetes Care 30 (2007) 2453-2457